The complex disease biology of ME/CFS & Long COVID
May 2025
Hello,
Welcome to this month's Insights, bringing you groundbreaking research and developments from PrecisionLife—driving precision medicine in chronic diseases.
This month, to mark World ME Day, we're describing the work we've published on that is improving the understanding of the disease biology and addressing unmet medical needs in ME/CFS and long COVID.
🧬 Reproducing Genetic Insights
Our latest publication demonstrates that the wide range of genetic risk factors that we identified for long COVID have now been confirmed to be associated with the disease across populations with diverse ancestries, with 92% of the genes reproduced.
This pivotal finding underscores the robustness of PrecisionLife’s AI-driven combinatorial analytics, providing strong evidence for developing globally effective precision diagnostic tools and therapeutic strategies.
Read the progress report highlighting significant advancements made in the first year of our collaborative research efforts on ME/CFS and Long COVID.
Key highlights include:
🧬 We’ve identified novel genetic drivers of disease 🛡️ Discovered a new class of actively protective drug targets 🧪 Developed rapid, non-invasive diagnostic tools 💊 Initiated clinical studies of repurposed, precision-guided therapies 🎯 Enabled differential triage across overlapping post-viral syndromes
Our dedicated resource page offers an extensive overview of PrecisionLife’s research activities, publications, and strategic initiatives focused on ME/CFS and Long COVID.
Engage with the latest findings and explore the opportunities these insights present for strategic translational medicine and clinical innovation.
🎤 Presentation: Precision Diagnostic Tests and Personalised Treatments for ME & Long COVID
International ME Conference, 30 May, 2025
PrecisionLife Co-founder & CBIO, Rowan Gardner, will present 'Precision Diagnostic Tests and Personalised Treatments for ME and Long COVID' at the International ME Conference on 30th May.
This session will provide strategic insights into our approach to transforming diagnostics and personalized treatments. We will share the recording when it becomes available. Follow @PrecisionLifeAI on LinkedIn to view it in your feed.
We invite you to join our upcoming webinar hosted by Action for ME on 6 June.
The session will feature PrecisionLife leaders detailing our recent breakthroughs, ongoing studies, and future directions aimed at significantly improving outcomes for patients with unmet medical needs.
PrecisionLife is a clinical-stage precision medicine company creating better diagnostic tools and more personalized treatment options to predict, treat, and prevent complex chronic diseases, which affect billions of patient lives and account for more than 80% of healthcare spending.
Our AI-driven insights hold the key to reducing the global burden of chronic diseases, improving the rate of successful R&D, and increasing healthspan.
